Letter

Depot medroxyprogesterone acetate and osteoporosis Monitor serum oestradiol concentration in users

BMJ 1994; 308 doi: 10.1136/bmj.308.6930.717 (Published 12 March 1994)
Cite this as: BMJ 1994;308:717.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. A Szarewski,
  2. B Hollingworth,
  3. J Guillebaud
  1. Margaret Pyke Centre, London W1V 6JB
  2. Department of Obstetrics and Gynaecology, Kettering General Hospital, Kettering NN16 8UZ.

    EDITOR, - T Cundy and colleagues again report the theoretical risk of oestrogen deficiency and osteoporosis in long term users of depot medroxyprogesterone acetate.1 Their previous study2 was criticised on methodological grounds,3 and the issue has not yet been resolved. As before, their small study is cross sectional rather than prospective. Once again, we do not know the bone densities of the women before they used depot medroxyprogesterone acetate. In addition, we are not given …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular